The human microbiome and its link in prostate cancer risk and pathogenesis

Katongole, Paul; Sande, Obondo J.; Joloba, Moses; Reynolds, Steven J.; Niyonzima, Nixon

doi:10.1186/s13027-020-00319-2

Cited by 42 publications

(35 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, profiling of the urinary microbiome revealed the prevalence of pro-inflammatory bacteria and uropathogens in the urinary tract of men with prostate cancer [107]. In addition to the urinary microbiome, normal and cancer prostate tissue is also associated with the presence of the microbiome [108]. Despite the role in inflammation, the microbiome can affect the prostate microenvironment while there is a pathophysiological association between the microbiome and prostate cancer [109,110].…”

Section: Microbiome Profiling and A Protective Role Of Probiotics In Pca Preventionmentioning

confidence: 99%

Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper

Golubnitschaja

Kubatka

Mazuráková

et al. 2022

Cancers

View full text Add to dashboard Cite

Prostate cancer (PCa) is reported as the most common malignancy and second leading cause of death in America. In Europe, PCa is considered the leading type of tumour in 28 European countries. The costs of treating PCa are currently increasing more rapidly than those of any other cancer. Corresponding economic burden is enormous, due to an overtreatment of slowly developing disease on one hand and underestimation/therapy resistance of particularly aggressive PCa subtypes on the other hand. The incidence of metastatic PCa is rapidly increasing that is particularly characteristic for young adults. PCa is a systemic multi-factorial disease resulting from an imbalanced interplay between risks and protective factors. Sub-optimal behavioural patterns, abnormal stress reactions, imbalanced antioxidant defence, systemic ischemia and inflammation, mitochondriopathies, aberrant metabolic pathways, gene methylation and damage to DNA, amongst others, are synergistically involved in pathomechanisms of PCa development and progression. To this end, PCa-relevant systemic effects are reflected in liquid biopsies such as blood patterns which are instrumental for predictive diagnostics, targeted prevention and personalisation of medical services (PPPM / 3P medicine) as a new paradigm in the overall PCa management. This strategic review article highlights systemic effects in prostate cancer development and progression, demonstrates evident challenges in PCa management and provides expert recommendations in the framework of 3P medicine.

show abstract

Section: Microbiome Profiling and A Protective Role Of Probiotics In Pca Preventionmentioning

confidence: 99%

Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper

Golubnitschaja

Kubatka

Mazuráková

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The latter Strept. Spp represented less than tenth, it is also presented in normal tissues, where it can transferred to prostate tissue and cause CBP leading to PCa [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]. One of the important points was the presence of pathogenic bacteria in cases of CBP infection, CBP causing one of the most dangerous in cases of PCa.…”

Section: Table 1 and Graph 1 Percentage Of Pathogenic Bacteria By Direct Identificationmentioning

confidence: 99%

“…E. coli detected in prostatic tissue and contributed as initiator of prostate inflammation and PCa [11]. The UT bacteria connected to genitourinary malignancies, especially PCa, was second cancer in males clear link between GT and UT bacteria and PCa risk [12]. PCa and peri-tumoral regions had higher Staph.…”

Section: Introductionmentioning

confidence: 99%

Highland Influence on Chronic-bacterial-prostatitis and Developing-reason of Prostate-cancer, KSA

Sabra¹

2021

BTBP

View full text Add to dashboard Cite

This work was for "Highland (HL) Influence on Chronic-bacterial-prostatitis (CBP) and Developing-reason of Prostate-cancer (PCa), KSA"; the purpose was to determine CBP percentage at HL "Taif"; and influence of location factors on CBP percentage and indication of its developing-reason to causing PCa. It may negatively affected other body organs and may reach death of males' society, affected marital and community life. Used medical methods for cases taster (CsT) from patients were diagnosed as suffered from CBP. That were used direct and indirect identification by "CHROMagar Orientation Medium", and "VITEK 2 System (BioMerieux, France)". The pathogenic bacteria were found in more than a quarter of the CsT as (26 and 29%). That were Staphylococcous aureus (Staph. aureus), Escherichia coli (E. coli), Staphylococcous epidermidis (Staph. epidermidis) and Streptococcus species (Strept. Spp) in (36.2%, 9.5%, 5.7% and 4.3%) respectively. Pathogenic bacteria Staph. aureus represented more than third of CsT. E. coli represented tenth and it was dangerous for its transmission from UT and GT easily. Staph. epidermidis was present on the skin and represented normal flora can easily contaminated. Strept. Spp represented less than tenth, can transferred to prostate tissue and cause CBP leading to PCa. Concluded the CBP infection was present in HL and had developing-reason for PCa, the conditions must followed to reduce it to prevent condition of turning into PCa. Recommended best periodic follow-up to detect CBP infection presence to protect against infection and its PCa developing-reason. Cases CBP infection must treated and PCa cases should not neglected or tolerated.

show abstract

“…Risk factors, such as diet and lifestyle are significant in the development of PC. [2][3][4][5] In addition to the mentioned risk factors, the increased PC prevalence observed throughout the world is also related to the prevalent use of the prostate-specific antigen (PSA) test. 6 One of the most common methods of detecting PC is to use the PSA test.…”

Section: Introductionmentioning

confidence: 99%

Metagenomics studies for the diagnosis and treatment of prostate cancer

et al. 2021

View full text Add to dashboard Cite

Aim: Mutation occurs in the prostate cell genes, leading to abnormal prostate proliferation and ultimately cancer. Prostate cancer (PC) is one of the most common cancers amongst men, and its prevalence worldwide increases relative to men's age. About 16% of the world's cancers are the result of microbes in the human body.Impaired population balance of symbiosis microbes in the human reproductive system is linked to PC development.Discussion: With the advent of metagenomics science, the genome sequence of the microbiota of the human body has been unveiled. Therefore, it is now possible to identify a higher range of microbiome changes in PC tissue via the Next Generation Technique, which will have positive consequences in personalized medicine. In this review, we intend to question the role of metagenomics studies in the diagnosis and treatment of PC. Conclusion:The microbial imbalance in the men's genital tract might have an effect on prostate health. Based on next-generation sequencing-generated data, Proteobacteria, Firmicutes, Actinobacteria, and Bacteriodetes are the nine frequent phyla detected in a PC sample, which might be involved in inducing mutation in the prostate cells that cause cancer.

show abstract

The human microbiome and its link in prostate cancer risk and pathogenesis

Cited by 42 publications

References 66 publications

Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper

Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper

Highland Influence on Chronic-bacterial-prostatitis and Developing-reason of Prostate-cancer, KSA

Metagenomics studies for the diagnosis and treatment of prostate cancer

Contact Info

Product

Resources

About